Rui Kang Pharmaceutical Group Investments Limited provided consolidated earnings guidance for the three months ended March 31, 2017. The group is expected to record a significant loss for the three months ended March 31, 2017, as opposed to a profit of approximately HKD 24.1 million (comprising loss from continuing operations of approximately HKD 11.4 million and profit from discontinued operation of approximately HKD 35.5 million) recorded for the corresponding period in 2016. The aforesaid loss for 2017 first quarter Period was mainly attributable to a significant net loss of approximately HKD 23.1 million on financial assets at fair value through profit or loss (as opposed to a net gain of approximately HKD 0.5 million for the corresponding period in 2016). During the 2017 first quarter Period, the group did not have any discontinued operation.